Top Markets
#1 Palladium Network Palladium Network +27.92%
#2 Siren Siren +24.42%
#3 Ankr Network Ankr Network +21.29%
#4 BankrCoin BankrCoin +18.65%
#5 Status Status +13.53%
#6 Pons Pons +9.90%
#7 Provenance Blockchain Provenance Blockchain +9.18%
#8 Hive Hive +8.50%
#9 Useless Coin Useless Coin +8.27%
#10 Wrapped Aave Ethereum WETH Wrapped Aave Ethereum WETH +7.84%
Coin of the day
Palladium Network Palladium Network
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Orchard Therapeutics plc Orchard Therapeutics plc

Orchard Therapeutics plc

ORTX
Kedudukan dalam Saham #18160
Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing... Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a therapeutic cellular drug that can address the illness with just one dose. The company markets Strimvelis, a gammaretroviral therapy approved for treating adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Orchard's clinical pipeline features several investigational therapies, including OTL-101 for ADA-SCID, OTL-200 targeting metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Early-stage research programs encompass OTL-203 for mucopolysaccharidosis type I, OTL-201 for MPS-IIIA, and OTL-202 for MPS IIIB. Furthermore, a strategic partnership with Pharming Group N.V. covers the research, development, production, and commercialization of OTL-105, an experimental ex vivo autologous hematopoietic stem cell gene therapy designed for hereditary angioedema. Established in 2015 as Orchard Rx Limited, Orchard Therapeutics plc is headquartered in London, UK.
Harga Saham
$16.70
Disegerakkan terakhir: 2024-02-02
Modal Pasaran
$210.34M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
GB
Perdagangan Orchard Therapeutics plc (ORTX)

Kategori

Healthcare
Nisbah P/E bagi Orchard Therapeutics plc (ORTX)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Orchard Therapeutics plc, nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Orchard Therapeutics plc dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.